“With all of the recent progress made at Outlook Therapeutics (OTLK) and the upcoming milestones over the next few months, we expect to be a very different company by the end of 2025,” commented Lawrence Kenyon, CFO and Interim CEO. “In 2025, we plan to start realizing our goal of providing patients, physicians and payers with an approved ophthalmic formulation of bevacizumab. This year, we anticipate beginning to generate the first revenue for Outlook Therapeutics with the launch of LYTENAVA in Germany and the UK and our BLA is on track for resubmission this quarter.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics Secures Funding and Board Restructures
- Outlook Therapeutics appoints Sukhtian as Chairman of the board of directors
- Outlook Therapeutics announces presentation of data from NORSE EIGHT
- Outlook Therapeutics enters into agreement for warrant inducement transaction
- Outlook Therapeutics’ ONS-5010 shown to be non-inferior to Lucentis in wet AMD